Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Sells 576 Shares of Becton, Dickinson and Company (NYSE:BDX)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA cut its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,983 shares of the medical instruments supplier’s stock after selling 576 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings in Becton, Dickinson and Company were worth $2,623,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Jeppson Wealth Management LLC increased its holdings in shares of Becton, Dickinson and Company by 4.0% in the third quarter. Jeppson Wealth Management LLC now owns 1,028 shares of the medical instruments supplier’s stock worth $266,000 after purchasing an additional 40 shares during the last quarter. CX Institutional increased its holdings in shares of Becton, Dickinson and Company by 3.0% in the third quarter. CX Institutional now owns 1,491 shares of the medical instruments supplier’s stock worth $385,000 after purchasing an additional 43 shares during the last quarter. U.S. Capital Wealth Advisors LLC increased its holdings in shares of Becton, Dickinson and Company by 3.4% in the third quarter. U.S. Capital Wealth Advisors LLC now owns 1,310 shares of the medical instruments supplier’s stock worth $339,000 after purchasing an additional 43 shares during the last quarter. Value Partners Investments Inc. increased its holdings in shares of Becton, Dickinson and Company by 5.2% in the third quarter. Value Partners Investments Inc. now owns 867 shares of the medical instruments supplier’s stock worth $225,000 after purchasing an additional 43 shares during the last quarter. Finally, Atlas Private Wealth Management increased its holdings in shares of Becton, Dickinson and Company by 2.9% in the third quarter. Atlas Private Wealth Management now owns 1,587 shares of the medical instruments supplier’s stock worth $410,000 after purchasing an additional 45 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BDX has been the topic of several research reports. Raymond James lifted their target price on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Barclays boosted their price objective on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $280.00.

Becton, Dickinson and Company Trading Up 0.6 %

Shares of NYSE BDX traded up $1.41 during trading hours on Tuesday, reaching $235.29. The stock had a trading volume of 318,007 shares, compared to its average volume of 1,382,620. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of 0.56. The firm has a market cap of $67.98 billion, a price-to-earnings ratio of 55.42, a P/E/G ratio of 1.93 and a beta of 0.43. The business’s fifty day moving average price is $239.81 and its two-hundred day moving average price is $241.99. Becton, Dickinson and Company has a 52-week low of $229.40 and a 52-week high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.39 by $0.29. The firm had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.73 billion. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. Becton, Dickinson and Company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.98 earnings per share. Analysts expect that Becton, Dickinson and Company will post 12.94 EPS for the current fiscal year.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, SVP Thomas J. Spoerel sold 282 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.31% of the stock is owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.